Lexicon Pharmaceuticals Cash Flow Statement
NASDAQ: LXRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
1.68-0.08 (-4.55%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Lexicon Pharmaceuticals free cash flow
In fiscal 2025, Lexicon Pharmaceuticals generated -$67.9 million of operating cash flow and spent $0 on capital expenditures. That left free cash flow of -$67.9 million, a free-cash-flow margin of -136.2% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Lexicon Pharmaceuticals cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20192020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -50.34M | -200.40M | -177.12M | -101.94M | -87.76M | -58.57M | 130.13M | -120.55M | -122.99M | -131.44M |
| Net Income growth (YoY) | — | — | — | — | — | -145.01% | — | — | — | — |
| Depreciation & Amortization | 621.00K | 534.00K | 554.00K | 427.00K | 292.00K | 2.93M | 3.65M | 3.68M | 3.40M | 2.06M |
| Stock-Based Compensation | 12.52M | 13.50M | 14.34M | 11.52M | 10.58M | 13.27M | 14.22M | 11.70M | 9.47M | 7.45M |
| Change in Working Capital | -28.43M | 13.64M | 5.56M | 718.00K | -13.12M | 33.03M | -55.63M | -46.54M | -64.76M | -59.79M |
| Operating Cash Flow | -67.85M | -178.78M | -161.90M | -88.85M | -87.02M | -142.97M | 113.81M | -148.61M | -185.39M | -175.63M |
| Capital Expenditures | 0 | -1.03M | -470.00K | -1.33M | -1.22M | -87.00K | -70.00K | -95.00K | -228.00K | -231.00K |
| Investing Cash Flow | 113.02M | -15.38M | -49.94M | -71.08M | 2.11M | 380.76M | -155.85M | 169.58M | 50.52M | 18.25M |
| Share Repurchases | — | -1.73M | -824.00K | -864.00K | -2.67M | -1.03M | -941.00K | -972.00K | -1.68M | -621.00K |
| Debt Issued | 0 | 0 | 49.96M | 48.87M | — | 0 | 0 | 12.53M | 145.91M | 0 |
| Debt Repaid | -48.00M | 0 | 0 | 48.87M | -11.70M | -216.58M | -1.28M | -14.53M | -2.28M | -2.02M |
| Financing Cash Flow | -48.50M | 238.35M | 187.96M | 142.21M | 22.71M | -147.64M | -2.23M | -2.24M | 149.93M | 987.00K |
| Net Change in Cash | -3.33M | 44.19M | -23.88M | -17.72M | -62.20M | 90.15M | -44.27M | 18.73M | 15.06M | -156.39M |
| Free Cash Flow | -67.85M | -179.81M | -162.37M | -90.18M | -88.24M | -143.06M | 113.74M | -148.70M | -185.62M | -175.86M |
This table shows 10 annual periods of Lexicon Pharmaceuticals's cash flow statement, from FY 2025 back to FY 2016, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow LXRX's reporting calendar. What is a cash flow statement?